...
【24h】

Editorial: Opioids 2019 & Beyond?

机译:社论:阿片类药物2019年及以外?

获取原文
获取原文并翻译 | 示例
           

摘要

One of the challenging issues for an editor is to come up with an interesting and timely issue. As a consumer of health information, and someone with a vested interest in the pain and palliative care fields, you obviously are aware that the topic of opioid pharmacotherapy continues to dominate news headlines. It seems a day does not go by where there is not a news story that involves opioids or the use of naloxone. To some extent this is not surprising, opioid analgesics have long been considered controversial. In my own career I have seen the pendulum swing with respect to the accepted clinical application of opioid analgesics. In my early pharmacy training in the 1980s opioid analgesics were discussed only in the context of severe acute pain and advanced cancer pain. As I completed my fellowship training in the late 1990s, the pendulum was swinging in favor of the use of opioid analgesics for patients with chronic non-cancer pain. As we enter 2019 it seems as though the pendulum has swung to a point whe e even use in severe acute pain and in palliative care is now in question.
机译:编辑的一个具有挑战性的问题是提出一个有趣和及时的问题。作为健康信息的消费者,以及患有痛苦和姑息的护理领域的有既得利益的人,您显然会意识到阿片类药物治疗的主题继续占据新闻头条新闻。似乎有一天没有通过涉及阿片类药物或使用纳洛酮的新闻故事的地方。在某种程度上,这并不令人惊讶,阿片类药物镇痛药长期被认为是有争议的。在我自己的职业生涯中,我已经看过垂直的临床临床应用的摆动。在我早期的药房培训,在20世纪80年代,仅在严重急性疼痛和晚期癌症疼痛的背景下讨论了阿片类镇痛药。正如我在20世纪90年代末完成的奖学金培训,钟摆有利于对慢性非癌症疼痛患者使用阿片类药物镇痛药。当我们进入2019时,似乎摆在甚至在严重急性疼痛和姑息治疗中都有甚至使用的点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号